NZ515685A - Use of riluzole for the treatment of multiple sclerosis - Google Patents

Use of riluzole for the treatment of multiple sclerosis

Info

Publication number
NZ515685A
NZ515685A NZ515685A NZ51568500A NZ515685A NZ 515685 A NZ515685 A NZ 515685A NZ 515685 A NZ515685 A NZ 515685A NZ 51568500 A NZ51568500 A NZ 51568500A NZ 515685 A NZ515685 A NZ 515685A
Authority
NZ
New Zealand
Prior art keywords
riluzole
treatment
multiple sclerosis
preparing
pharmaceutical composition
Prior art date
Application number
NZ515685A
Other languages
English (en)
Inventor
Chris Polman
Original Assignee
Vereniging Voor Christelijk Wetenschappelijk Onderwijs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vereniging Voor Christelijk Wetenschappelijk Onderwijs filed Critical Vereniging Voor Christelijk Wetenschappelijk Onderwijs
Publication of NZ515685A publication Critical patent/NZ515685A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
NZ515685A 1999-06-04 2000-06-02 Use of riluzole for the treatment of multiple sclerosis NZ515685A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99201788 1999-06-04
US17432800P 2000-01-04 2000-01-04
PCT/IB2000/000933 WO2000074676A1 (en) 1999-06-04 2000-06-02 Use of riluzole for the treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
NZ515685A true NZ515685A (en) 2002-12-20

Family

ID=56290027

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ515685A NZ515685A (en) 1999-06-04 2000-06-02 Use of riluzole for the treatment of multiple sclerosis

Country Status (11)

Country Link
EP (2) EP1552831B1 (enExample)
JP (1) JP2003522121A (enExample)
AT (2) ATE419851T1 (enExample)
AU (1) AU777537B2 (enExample)
CA (1) CA2375874A1 (enExample)
DE (1) DE60017733T2 (enExample)
ES (1) ES2235896T3 (enExample)
NZ (1) NZ515685A (enExample)
PT (1) PT1187612E (enExample)
SI (1) SI1187612T1 (enExample)
WO (1) WO2000074676A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1100504A2 (en) 1998-07-02 2001-05-23 Eisai Co., Ltd. Pharmaceutical compositions and their uses for treatment of demyelinating disorders
US6872739B1 (en) * 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
IL136687A0 (en) * 2000-06-12 2001-06-14 Mor Research Applic Ltd Pharmaceutical composition for the treatment of multiple sclerosis
EP1778286A4 (en) * 2004-03-03 2009-04-08 Teva Pharma COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE
ITMI20061274A1 (it) * 2006-06-30 2008-01-01 Consiglio Nazionale Ricerche Vettori nanoparticellari lipidici contenenti riluzolo e composizioni farmaceutiche che li contengono
EP2228054A1 (en) 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
WO2010113225A1 (en) * 2009-03-30 2010-10-07 Yutoku Pharmaceutical Industries Co., Ltd. Riluzole-containing transdermal patch
CA2967659A1 (en) * 2014-11-21 2016-05-26 Biohaven Pharmaceutical Holding Company Ltd. Sublingual administration of riluzole
US10258611B2 (en) * 2014-11-26 2019-04-16 Medicinova, Inc. Combination of ibudilast and riluzole and methods of using same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
JPH11513698A (ja) * 1995-10-25 1999-11-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 神経保護物質およびパーフルオロケミカルの注射剤
JP3117725B2 (ja) * 1995-11-15 2000-12-18 山之内製薬株式会社 カイニン酸神経細胞毒性阻害剤及びピリドチアジン誘導体
US5728728A (en) * 1996-04-10 1998-03-17 Kozachuk; Walter E. Methods of providing neuroprotection
IL119989A0 (en) * 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
JP4120713B2 (ja) * 1997-09-04 2008-07-16 大塚製薬株式会社 多発性硬化症治療剤
US6872739B1 (en) * 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis

Also Published As

Publication number Publication date
EP1552831B1 (en) 2009-01-07
PT1187612E (pt) 2005-05-31
ES2235896T3 (es) 2005-07-16
WO2000074676A1 (en) 2000-12-14
AU777537B2 (en) 2004-10-21
DE60017733T2 (de) 2006-01-12
DE60017733D1 (de) 2005-03-03
SI1187612T1 (en) 2005-06-30
EP1552831A1 (en) 2005-07-13
ATE419851T1 (de) 2009-01-15
ATE287713T1 (de) 2005-02-15
JP2003522121A (ja) 2003-07-22
EP1187612A1 (en) 2002-03-20
EP1187612B1 (en) 2005-01-26
AU5421900A (en) 2000-12-28
CA2375874A1 (en) 2000-12-14

Similar Documents

Publication Publication Date Title
WO1996032003A3 (en) Tetrahydroimidazopyridoindolediones and their use as medicaments
MY134892A (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
MX9704377A (es) Uso de pramipexole como agente neuroprotector.
EP1193270A3 (en) Pyrrolobenzodiazepines
AP9901534A0 (en) Pharmaceutical formulations.
DE60112974D1 (en) Carbolinderivate
MX9700885A (es) Nuevas heteroariloxazolidinonas.
AU7031500A (en) Therapeutic quinazoline compounds
PL340836A1 (en) Novel compounds
ZA977482B (en) 7α(ξ-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7α-(ξ-aminoalkyl)-estratrienes as well as their use for the production of pharmaceutical agents.
SE9704546D0 (sv) Novel compounds
MX9700886A (es) Nuevas oxazolidinonas sustituidas.
MX9605023A (es) Compuestos substituidos de imidazolidin-2,4-diona como substancias farmaceuticamente activas.
GB9415840D0 (en) Nozzle
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
DE60216233D1 (en) Carbolinderivate
AU7622000A (en) Compounds for the treatment of viral-mediated diseases
AU3354895A (en) Novel medicinal use of 5ht3 antagonist
AU2001266575A1 (en) Chemical compounds
MX9708696A (es) Cefalosporinas antibacterianas.
ZA922297B (en) Crystalline tiababine monohydrate,its preparation and use
GB9907571D0 (en) Compounds
ZA973622B (en) Use of forms of hyaluronic acid (HA) for the treatment of cancer.
HUP9802634A3 (en) Use of benzimidazoles for the manufacture of pharmaceutical compositions for the treatment of leukemia
IL109866A0 (en) Crystalline 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (+) l-hydrogentartrate, its preparation and pharmaceutical compositions containing it

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
ASS Change of ownership

Owner name: VERENIGING VOOR CHRISTELIJK WETENSCHAPPELIJK O, NL

Free format text: OLD OWNER(S): VERENIGING VOOR CHRISTELIJK WETENSCHAPPELIKJK ONDERWIJS

RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 02 JUN 2020 BY COMPUTER PACKAGES INC

Effective date: 20130709

EXPY Patent expired